Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0IOMGE
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
JNJ-89862175
|
|||||
| Synonyms |
JNJ-89862175 ;JNJ-89862175;JNJ-2175
Click to Show/Hide
|
|||||
| Organization |
Johnson & Johnson (Top20 MNC) (Originator)
|
|||||
| Drug Status |
Phase 1
|
|||||
| Antibody Name |
Anti-ENPP3 antibody
|
Antibody Info | ||||
| Antigen Name |
Ectonucleotide pyrophosphatase/phosphodiesterase family member 3 (ENPP3)
|
Antigen Info | ||||
| Payload Name |
Undisclosed
|
|||||
| Therapeutic Target |
Stimulator of interferon genes protein (STING1)
|
Target Info | ||||
| Linker Name |
Undisclosed
|
|||||
| Conjugate Type |
Undisclosed
|
|||||
The indication landscape of This ADC(2027 Update)
The clinical trial pipeline of This ADC(2027 Update)
| Indication | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | New Drug Application | Approved | ||
|---|---|---|---|---|---|---|---|---|---|
| Endometrial cancer |
1 Trials
|
||||||||
| Kidney cancer |
1 Trials
|
||||||||
| Lung cancer |
1 Trials
|
||||||||
| Ovarian cancer |
1 Trials
|